DOP2014000011A - Compuesto inhibidor de la señalización de la trayectoria notch - Google Patents

Compuesto inhibidor de la señalización de la trayectoria notch

Info

Publication number
DOP2014000011A
DOP2014000011A DO2014000011A DO2014000011A DOP2014000011A DO P2014000011 A DOP2014000011 A DO P2014000011A DO 2014000011 A DO2014000011 A DO 2014000011A DO 2014000011 A DO2014000011 A DO 2014000011A DO P2014000011 A DOP2014000011 A DO P2014000011A
Authority
DO
Dominican Republic
Prior art keywords
notch
signaling
trajectory
inhibitor compound
compound
Prior art date
Application number
DO2014000011A
Other languages
English (en)
Inventor
Gregory Alan Stephenson
Philip Arthur Hipskind
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2014000011A publication Critical patent/DOP2014000011A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto, o una sal o hidrato farmacéuticamente aceptable, y una composición farmacéutica que contiene el compuesto, o una sal o hidrato farmacéuticamente aceptable, útil como un inhibidor de la señalización de la trayectoria Notch para el tratamiento de cáncer.
DO2014000011A 2011-07-27 2014-01-22 Compuesto inhibidor de la señalización de la trayectoria notch DOP2014000011A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US201161560486P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
DOP2014000011A true DOP2014000011A (es) 2014-07-31

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000011A DOP2014000011A (es) 2011-07-27 2014-01-22 Compuesto inhibidor de la señalización de la trayectoria notch

Country Status (36)

Country Link
US (1) US8569286B2 (es)
EP (1) EP2736920B1 (es)
JP (1) JP6027110B2 (es)
KR (1) KR101578309B1 (es)
CN (1) CN103732612B (es)
AP (1) AP4080A (es)
AR (1) AR087107A1 (es)
AU (1) AU2012287251B2 (es)
BR (1) BR112014001600B1 (es)
CA (1) CA2841178C (es)
CL (1) CL2014000175A1 (es)
CO (1) CO6862159A2 (es)
CR (1) CR20140036A (es)
CY (1) CY1116645T1 (es)
DK (1) DK2736920T3 (es)
DO (1) DOP2014000011A (es)
EA (1) EA023044B1 (es)
EC (1) ECSP14013179A (es)
ES (1) ES2544937T3 (es)
GT (1) GT201400012A (es)
HR (1) HRP20150771T1 (es)
HU (1) HUE027534T2 (es)
IL (1) IL229988A (es)
JO (1) JO3148B1 (es)
MA (1) MA35611B1 (es)
ME (1) ME02171B (es)
MX (1) MX356536B (es)
MY (1) MY184303A (es)
PE (1) PE20141061A1 (es)
PH (1) PH12014500215B1 (es)
PL (1) PL2736920T3 (es)
PT (1) PT2736920E (es)
RS (1) RS54135B1 (es)
SI (1) SI2736920T1 (es)
TW (1) TWI568730B (es)
WO (1) WO2013016081A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
SG10201913587WA (en) 2016-02-05 2020-02-27 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
KR102418765B1 (ko) * 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료를 위한 Notch 및 CDK4/6 억제제의 조합 요법
KR102418766B1 (ko) * 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
US10688104B2 (en) 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
US20190209581A1 (en) * 2016-08-31 2019-07-11 Eli Lilly And Company Dosage regimen for treatment of solid tumors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
DK3552017T3 (da) 2016-12-09 2022-05-16 Denali Therapeutics Inc Forbindelser, der er anvendelige som ripk1-inhibitorer
JP2020507605A (ja) 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Bcma関連癌および自己免疫疾患の治療のための併用療法
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
EP3706754A1 (en) 2017-11-06 2020-09-16 Juno Therapeutics, Inc. Combination of a cell therapy and a gamma secretase inhibitor
MX2020011826A (es) * 2018-05-06 2021-01-15 Ayala Pharmaceuticals Inc Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas.
MX2021003773A (es) 2018-10-02 2021-07-16 Frequency Therapeutics Inc Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
BR112021020141A2 (pt) 2019-04-08 2021-12-21 Frequency Therapeutics Inc Combinação de chir99021 e ácido valpróico para tratamento de perda auditiva
WO2023137035A1 (en) 2022-01-12 2023-07-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901343T2 (xx) * 1996-12-23 1999-09-21 Elan Pharmaceuticals, Inc. Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
AU4710199A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO1999067219A1 (en) 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
ATE402934T1 (de) 2003-02-04 2008-08-15 Hoffmann La Roche Malonamidderivate als gamma-secretaseinhibitoren
AU2004270361B2 (en) 2003-09-09 2009-06-25 F. Hoffmann-La Roche Ag Malonamide derivatives blocking the activity of gama-secretase
PT1673347E (pt) 2003-10-06 2015-11-02 Hoffmann La Roche Derivados de dibenzo-azepina e benzo-diazepina substituídos, úteis como inibidores de secretase gama
KR101169628B1 (ko) 2006-03-27 2012-07-30 에프. 호프만-라 로슈 아게 감마 세크레테아제 저해제로서의 말론아미드 유도체
AU2008209861B2 (en) * 2007-02-02 2012-08-09 F. Hoffmann-La Roche Ag 6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl derivatives
MA33076B1 (fr) 2008-01-11 2012-03-01 Hoffmann La Roche Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
US8637493B2 (en) * 2009-11-12 2014-01-28 University Of Massachusetts Methods for treating glioblastoma

Also Published As

Publication number Publication date
AR087107A1 (es) 2014-02-12
HUE027534T2 (en) 2016-11-28
HRP20150771T1 (hr) 2015-08-28
PE20141061A1 (es) 2014-09-06
JO3148B1 (ar) 2017-09-20
KR20140026624A (ko) 2014-03-05
EA201490161A1 (ru) 2014-04-30
MY184303A (en) 2021-03-31
CR20140036A (es) 2014-03-21
IL229988A (en) 2017-07-31
ECSP14013179A (es) 2014-03-31
EA023044B1 (ru) 2016-04-29
GT201400012A (es) 2014-07-16
BR112014001600B1 (pt) 2022-09-13
PT2736920E (pt) 2015-09-16
AU2012287251B2 (en) 2015-05-14
DK2736920T3 (en) 2015-07-20
AU2012287251A1 (en) 2014-01-30
BR112014001600A2 (pt) 2017-02-21
ES2544937T3 (es) 2015-09-07
SI2736920T1 (sl) 2015-08-31
CL2014000175A1 (es) 2014-08-22
CA2841178A1 (en) 2013-01-31
MA35611B1 (fr) 2014-11-01
US8569286B2 (en) 2013-10-29
KR101578309B1 (ko) 2015-12-16
EP2736920A1 (en) 2014-06-04
MX356536B (es) 2018-06-01
CO6862159A2 (es) 2014-02-10
US20130029972A1 (en) 2013-01-31
TW201315732A (zh) 2013-04-16
RS54135B1 (sr) 2015-12-31
PL2736920T3 (pl) 2015-11-30
JP2014527042A (ja) 2014-10-09
PH12014500215A1 (en) 2014-03-17
EP2736920B1 (en) 2015-07-01
NZ618891A (en) 2015-12-24
MX2014001084A (es) 2014-02-27
AP2014007362A0 (en) 2014-01-31
CN103732612B (zh) 2015-09-23
CY1116645T1 (el) 2017-03-15
WO2013016081A1 (en) 2013-01-31
PH12014500215B1 (en) 2018-09-07
JP6027110B2 (ja) 2016-11-16
TWI568730B (zh) 2017-02-01
CN103732612A (zh) 2014-04-16
ME02171B (me) 2015-10-20
HK1194086A1 (en) 2014-10-10
CA2841178C (en) 2016-12-20
AP4080A (en) 2017-03-29

Similar Documents

Publication Publication Date Title
ECSP14013179A (es) Compuesto inhibidor de la señalización de la trayectoria notch
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
PE20150887A1 (es) Compuestos de benceno sustituidos
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
PE20151654A1 (es) Inhibidores de cdc7
UY33498A (es) Combinaciones de inhibidores de quinasas para el tratamiento de cancer
MX2018000916A (es) Derivados de benzodiazepina como inhibidores de rsv.
MX374513B (es) Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
BR112014028042A2 (pt) inibidores de nampt
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
GT201300263A (es) Combinación de un inhibidor de cinasa de fosfatidilinositol-3 (pi3k) y un inhibidor de mtor
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
AR125339A2 (es) Compuesto inhibidor de la señalización de la trayectoria notch
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch
ECSP099729A (es) Sales monoclorhidrato de un inhibidor de histona deacetilasa
TN2013000515A1 (en) Notch pathway signaling inhibitor compound